Search results
Results From The WOW.Com Content Network
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat B-cell lymphomas, including follicular lymphoma. [3] [6]Side effects include hypersensitivity reactions, serious infections, low blood cell counts, and a weakened immune system. [6]
Multinational health care companies (1 C, 5 P) P. Personal care companies (11 C, 13 P) Pharmaceutical companies (14 C, 3 P) V. Veterinary companies (3 C, 3 P) W.
Vizient Inc., based in Irving, Texas, is a corporation that serves over 5,000 not-for-profit health system members and their affiliates, including 1,360 acute care hospitals. Founded in 2016, it is a successor company to VHA, Inc. , founded in 1977 as a network of not-for-profit health care organizations working in clinical, financial, and ...
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, in the United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products.
One Medical was founded by Tom Lee in 2007. The company grew from a single San Francisco clinic to more than 72 locations across the United States, including 29 clinics in the greater San Francisco Bay Area. [3] [4] 1Life Healthcare, Inc. serves as an administrative and managerial services company for physician-owned professional corporations. [7]
National HealthCare Corporation is an American healthcare services provider. The company was founded in 1971 and is based in Murfreesboro, Tennessee. [2] The services of the company include long-term diverse nursing and rehabilitative care to healthcare centers, facilities and hospitals in 11 states primarily in the southeastern United States.
The safety and efficacy of ciltacabtagene autoleucel were evaluated in CARTITUDE-1 (NCT03548207), an open label, multicenter clinical trial evaluating ciltacabtagene autoleucel in 97 participants with relapsed or refractory multiple myeloma who received at least three prior lines of therapy which included a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody ...